Angiotech Announces Changes to Management and Board of Directors

       Angiotech Announces Changes to Management and Board of Directors

PR Newswire

VANCOUVER, Oct. 11, 2013

VANCOUVER, Oct.  11,  2013  /PRNewswire/  -  Angiotech  Pharmaceuticals,  Inc. 
("Angiotech") announced today  that its  shareholders and  Board of  Directors 
have approved changes to the Company's executive management team and Board  of 
Directors.

Effective October  8, Thomas  Bailey and  Angiotech mutually  agreed that  Mr. 
Bailey would  transition  from  his  current role  as  President  and  CEO  of 
Angiotech, and into  a Board  role. As  of that  same date,  at the  Company's 
Annual General Meeting, Mr. Bailey  was elected by the Company's  shareholders 
to serve on Angiotech's Board of Directors. In addition, Kurt Cellar,  Jeffrey 
Goldberg, Don Casey, Bradley Karro and Omar Vaishnavi were also re-elected  to 
the Board of Directors.

Mr. Victor Diaz, who has been named President and Chief Operating Officer, and
Ms. Tammy  Neske,  Chief  Business  Officer,  will  report  to  the  Board  of 
Directors,  and  their  respective  roles  and  responsibilities  will  remain 
generally unchanged.  Mr. Jay  Dent  will continue  to  serve as  Senior  Vice 
President and Chief Financial Officer.

"We would like to offer thanks, on  behalf of the Board and our  shareholders, 
to Tom for his dedication and his many significant contributions during his 10
years with Angiotech,"  said Kurt  Cellar and Jeffrey  Goldberg, Co-Chairs  of 
Angiotech's Board  of  Directors.  "Tom's determination  and  experience  were 
critical in enabling  the Company to  navigate many challenges,  and the  hard 
work and operating acumen of  Tom and his team  set the stage for  Angiotech's 
successful return to growth  and profitability during the  past two years.  We 
look forward to continuing our work together as active members of the Board of
Directors."

"I would like  to offer my  sincere personal thanks  to our shareholders,  our 
Board, and most importantly to our dedicated executive team and employees, who
have offered me the great privilege of  working with them, and who have  stood 
with me through both challenges and successes," said Mr. Bailey. "Our  recent 
results, and the returns we've delivered  to shareholders, have been due to  a 
unique and  highly  cohesive  team  effort among  our  Board,  management  and 
employees, and  I  very  much  look forward  to  contributing  to  Angiotech's 
continued success as a member of our Board of Directors."

Subsequent to the divestiture of its Interventional Products Business to Argon
Medical this past spring, Angiotech changed the name of its operating business
to  Surgical   Specialties  Corporation.   Surgical  Specialties   Corporation 
develops, manufactures and markets  specialized surgical instruments, for  its 
own brands as well as for  selected private label and OEM customers.  Surgical 
Specialties offers  one  of  the most  comprehensive  portfolios  of  surgical 
blades, needles and sutures  available for the  specialty surgery market,  and 
has trusted customer relationships and partnerships in the dental, ophthalmic,
plastic surgery, dermatology,  orthopedics, urology,  microsurgery and  trauma 
specialties.

Forward Looking Statements

Statements contained in this  press release that are  not based on  historical 
fact, including without limitation statements containing the words "believes,"
"may," "plans,"  "will," "estimates,"  "continues," "anticipates,"  "intends," 
"expects" and  similar  expressions, constitute  "forward-looking  statements" 
within the meaning of the Private Securities Litigation Reform Act of 1995 and
constitute "forward-looking information" within the meaning of applicable U.S.
and Canadian securities  laws. All such  statements are made  pursuant to  the 
"safe harbor" provisions of applicable securities legislation. Forward-looking
statements may involve, but are not  limited to, comments with respect to  our 
objectives and  priorities  in  2013  and beyond,  our  strategies  or  future 
actions, our targets, expectations for our financial condition and the results
of, or  outlook for,  our  operations, research  and development  and  product 
development. Such forward-looking statements involve known and unknown  risks, 
uncertainties and other factors that may  cause the actual results, events  or 
developments to be  materially different  from any future  results, events  or 
developments expressed  or implied  by such  forward-looking statements.  Many 
such known risks, uncertainties  and other factors are  taken into account  as 
part of  our  assumptions  underlying  these  forward-looking  statements  and 
include, among others, the following: general economic and business conditions
in the United States, Canada and the other regions in which we operate; market
demand; competition;  technological changes  that  could impact  our  existing 
products  or  our  ability  to  develop  and  commercialize  future  products; 
governmental legislation and  regulations and  changes in, or  the failure  to 
comply  with,  governmental  legislation  and  regulations;  availability   of 
financial reimbursement coverage from governmental and third-party payers  for 
products and  related  treatments; adverse  results  or unexpected  delays  in 
pre-clinical and  clinical  product development  processes;  adverse  findings 
related to the safety and/or efficacy of our products or products sold by  our 
partners; decisions, and the  timing of decisions,  made by health  regulatory 
agencies regarding approval  of our technology  and products; the  requirement 
for funding to conduct research  and development, to expand manufacturing  and 
commercialization activities;  and  any  other factors  that  may  affect  our 
performance. In addition, our business  is subject to certain operating  risks 
that may  cause  any  results  expressed or  implied  by  the  forward-looking 
statements in this press release to differ materially from our actual results.
These operating risks include: our ability to successfully manufacture, market
and sell our products; changes in our business strategy or development  plans; 
our ability  to  attract  and  retain  qualified  personnel;  our  ability  to 
successfully complete pre-clinical and  clinical development of our  products; 
our failure  to  obtain patent  protection  for discoveries;  loss  of  patent 
protection   resulting   from   third-party   challenges   to   our   patents; 
commercialization limitations imposed by patents owned or controlled by  third 
parties; our ability to obtain rights to technology from licensors;  liability 
for patent claims and other claims asserted against us; our ability to  obtain 
and enforce timely patent and  other intellectual property protection for  our 
technology and products; the ability to enter into, and to maintain, corporate
alliances relating to the development and commercialization of our  technology 
and  products;  market  acceptance  of   our  technology  and  products;   the 
availability of capital to finance our activities; our ability to service  our 
debt obligations; or any other factors. Given these uncertainties, assumptions
and risk factors, investors are cautioned not to place undue reliance on  such 
forward-looking statements.  Except  as  required  by  law,  we  disclaim  any 
obligation to update any  such factors or to  publicly announce the result  of 
any revisions to any of the forward-looking statements contained in this press
release to reflect future results, events or developments.

©2013 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

SOURCE Angiotech Pharmaceuticals, Inc.

Contact:

Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(604) 221-7933ir@angio.com
 
Press spacebar to pause and continue. Press esc to stop.